HistoSonics announced today that Elevance Health (formerly Anthem) issued a positive medical policy for histotripsy to treat liver tumors.
The policy went into effect yesterday, Oct. 21, 2025. It expands insurance coverage across Elevance’s commercial, Medicare and Medicaid plans in 14 states. Those states include California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia and Wisconsin.
Minneapolis-based HistoSonics says the new policy broadens access to its incisionless, non-thermal therapy for approximately 45.4 million members.
The company develops the Edison platform that uses focused ultrasound energy to provide histotripsy for the noninvasive destruction of tumors. Using a robotic arm, Edison mechanically destroys and liquifies targeted tissue and tumors without the invasiveness or toxicity of traditional procedures. The platform received its first FDA de novo authorization in the U.S. in 2023. It’s the first and only histotripsy platform cleared for clinical use globally.
New insurance coverage for Edison follows several recent milestones for HistoSonics. Those include the acquisition of a $2.25 billion majority stake by a syndicate of investors, as well as $250 million in growth financing.
The company says Elevance’s decision follows “a growing wave” of payer adoption in the U.S. In July, Highmark Blue Cross Blue Shield issued four new medical policy decisions covering histotripsy for liver tumors. That win came shortly after a May coverage nod that marked the company’s first major insurance coverage for the non-invasive treatment for primary and metastatic liver tumors.
“This coverage expansion by Elevance Health represents another critical milestone in increasing access to histotripsy for patients who urgently need non-invasive treatment options,” said Mike Blue, chair and CEO of HistoSonics. “We are deeply grateful to our clinical partners who continue to generate strong evidence validating the safety, precision, and effectiveness of histotripsy, and to the growing number of payers recognizing its value in improving outcomes for patients with liver tumors. Liver metastases contribute to nearly half of all cancer-related deaths worldwide, highlighting the urgent need for non-invasive solutions that can improve both survival and quality of life.”
